These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12163627)

  • 1. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
    Lowe VJ; Wiseman GA
    J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
    [No Abstract]   [Full Text] [Related]  

  • 2. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
    Kostakoglu L
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
    Iagaru A; Wang Y; Mari C; Quon A; Goris ML; Horning S; Gambhir SS
    Hell J Nucl Med; 2008; 11(3):153-6. PubMed ID: 19081857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
    [No Abstract]   [Full Text] [Related]  

  • 9. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
    Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
    Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET in the management of lymphoma: a clinical perspective.
    Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
    [No Abstract]   [Full Text] [Related]  

  • 12. [FDG-PET in Hodgkin lymphoma].
    Kobe C; Dietlein M; Mauz-Körholz C; Engert A; Borchmann P; Sabri O; Schober O; Schicha H; Kluge R
    Nuklearmedizin; 2008; 47(6):235-8; quiz N75-6. PubMed ID: 19057796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
    Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Lorenz WJ; Maier-Borst W; van Kaick G
    Eur J Nucl Med; 1995 May; 22(5):434-42. PubMed ID: 7641752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy.
    Lavely WC; Delbeke D; Greer JP; Morgan DS; Byrne DW; Price RR; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):307-15. PubMed ID: 12957239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG positron emission tomography in lymphoma.
    Tecnologica MAP Suppl; 2000 Jan; ():9-10. PubMed ID: 10848116
    [No Abstract]   [Full Text] [Related]  

  • 18. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring response with FDG-PET: methodological aspects.
    Allen-Auerbach M; Weber WA
    Oncologist; 2009 Apr; 14(4):369-77. PubMed ID: 19357228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.